Navigation Links
Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting
Date:11/8/2007

abi-HB products, respectively, compared to $19.5 million in the third quarter of 2006. Current period revenues also reflect a $3.3 million charge related to an unfavorable court ruling that vacated a portion of the $4.5 million awarded to us on February 9, 2007 in an arbitration relating to a contract manufacturing agreement with Inhibitex, Inc. We will vigorously challenge this ruling on appeal. Excluding this charge, segment revenues increased by $3.9 million, or 20%, from the third quarter of 2006. This increase was driven by a $3.7 million increase in antibody sales principally from higher sales of Tetanus and Anti-D antibodies.

Nabi Biologics research and development expenses were $10.7 million for the third quarter ended September 30, 2007, compared to $5.1 million for the same period last year. This increase reflects the acceleration of Nabi's IVIG development program along with costs associated with obtaining the Biologics Licensing Application for Nabi-HB intravenous. We also recorded a $2.7 million charge in the current quarter in connection with the termination of future obligations associated with the development of ATG-Fresenius. Nabi Biologics had an operating loss of $6.4 million for the three months ended September 29, 2007 compared to an operating loss of $2.7 million for the comparable prior year period.

Nabi Pharmaceuticals

Nabi Pharmaceuticals posted an operating loss of $2.2 million in the third quarter of 2007 compared to a loss of $5.3 million in the third quarter of 2006. Research and development costs were $2.2 million for the three months ended September 29, 2007, compared to $5.1 million for the same period last year. This decrease reflects lower spending associated with our Gram-positive programs, including StaphVAX. NicVAX expenses were also lower in the current quarter as third quarter 2006 expenses included the initiation of the NicVAX Phase II proof of concept trial. NicVAX expenses were partially offset by funding f
'/>"/>

SOURCE Nabi Biopharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
2. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
3. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
4. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
5. HEI, Inc. Announces Sale of RFID Division Assets
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
7. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
8. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
9. Brooke Franchise Corporation Announces Selected July Results
10. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2015)... ... August 01, 2015 , ... Tina Wilcoxson, owner of Freeport Maine’s ... given that honor by the National Retail Federation, the largest retail trade association in ... of three Maine business owners to be named as such. According to the NRF’s ...
(Date:8/1/2015)... Dallas, TX (PRWEB) , ... August 01, 2015 , ... ... support for the March4thforWellBeing foundation, making hers the very first small business donation to ... and look beautiful for over thirty years. Her legacy includes a complete line of ...
(Date:7/31/2015)... ... July 31, 2015 , ... When the weather turned hot ... their new type of sod called Leisure Time(TM) zoysia . It's nicknamed LTZ(TM) ... To commemorate introduction of this new type of sod, Super-Sod is giving away red ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... industry players to know in predictive health analytics , Jvion continues to ... The firm creates predictive software that targets patient and population level illness to ...
(Date:7/31/2015)... FL (PRWEB) , ... July 31, 2015 , ... ... announced an important workshop at its new True North Conference Center. The medical ... so that the Jacksonville community may be more aligned in the effort to ...
Breaking Medicine News(10 mins):Health News:Local Retail Advocate Wins National Recognition 2Health News:March4thforWellBeing Foundation Kickoff 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3
... awareness about the,prevalence of Traumatic Brain Injury (TBI) ... Healthcare Alliance has contributed,$50,000 to the Bob Woodruff ... the Department of Defense, current reports suggest that,sixty ... the Global War,on Terror have been impacted by ...
... In recognition of,Diabetes Awareness Month, The ... launched a special,feature, which highlights the ... provides,important information to further the understanding ... can be found at, http://www.healthcentral.com/diabetes/diabetes-awareness-month.html, ,promotes ...
... Nov. 6 Kiadis Pharma,announced today that its ... by the US Food and Drug Administration (FDA) ... Graft versus Host Disease (GvHD),following allogeneic bone marrow ... and anticipated to enter clinical phase III,studies in ...
... concerns about the further underperformance and ... deterioration of shareholder value., ... Taft-Hartley and union health benefit and pension fund trustees ... of Employee Benefit Plans conference. The conference is,considered a ...
... advanced liver disease who did not respond to ... liver enzymes, viral levels, and liver inflammation following ... did not slow or prevent the progression of ... clinical trial, Hepatitis C Antiviral Long-Term Treatment Against ...
... LONG BEACH, Calif., Nov. 6 A class action,lawsuit ... Court,against S&F Management Company, Inc.; S&F Management Company, LLC; ... facilities,around the state [See list by city at end ... his Attorney in Fact, Virginia Boone, on his behalf,and ...
Cached Medicine News:Health News:TriWest Contributes $50,000 to Bob Woodruff Family Fund for Traumatic Brain Injury 2Health News:The HealthCentral Network's MyDiabetesCentral.com Promotes Awareness of Diabetes 2Health News:The HealthCentral Network's MyDiabetesCentral.com Promotes Awareness of Diabetes 3Health News:FDA Grants Kiadis Pharma Lead Product ATIR Orphan Drug Designation 2Health News:FDA Grants Kiadis Pharma Lead Product ATIR Orphan Drug Designation 3Health News:Labor Union Coalition Alerts Industry Analysts About Rite Aid 2Health News:Labor Union Coalition Alerts Industry Analysts About Rite Aid 3Health News:Hepatitis C treatment reduces the virus but serious liver problems may progress 2Health News:Class Action Lawsuit Filed Against 15 California Nursing Homes 2Health News:Class Action Lawsuit Filed Against 15 California Nursing Homes 3
(Date:7/30/2015)... DIEGO, July 30, 2015  ResMed Inc. (NYSE: ... June 30, 2015.  Revenue for the quarter was $453.1 ... ended June 30, 2014 (a 17 percent increase on ... consistent with the quarter ended June 30, 2014.  Diluted ... with the quarter ended June 30, 2014.  ...
(Date:7/30/2015)... Calif. , July 30, 2015  EP ... /Alcon executives have recently contacted the Company about ... begin as early as Monday, August 3, 2015.  ... quoted as saying that the coming electronic contact ... of dollars over the next several years.  Novartis ...
(Date:7/30/2015)... , July 30, 2015  Unichem Pharmaceuticals ( ... one lot of Hydrochlorothiazide tablets 25 mg 1000-count bottle ... as a precautionary measure due to the identification of ... product. The risk associated with mistakenly ... is the increased probability of experiencing Clopidogrel,s side effects ...
Breaking Medicine Technology:ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2
Cementless hip stem revisions offering optimal version setting for each patient. Compatible with modular link ceramic or cobalt chromium femoral heads with up to 4 neck lengths, or the link saddle de...
The proximally modular S-ROM Total Hip System provides custom capability at non-custom prices and is competitive with conventional porous coated systems....
Exactech's AcuMatch C-Series (Cemented Femoral Stem) is designed to provide solutions to the problems which compromise both the short and long term successful outcome of cemented hip arthroplasty....
Severe revision options for the knee and hip...
Medicine Products: